Peapod Lane Capital LLC Sells 167,445 Shares of Oramed Pharmaceuticals Inc. $ORMP

Peapod Lane Capital LLC lessened its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 66.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 84,779 shares of the biotechnology company’s stock after selling 167,445 shares during the period. Peapod Lane Capital LLC owned 0.21% of Oramed Pharmaceuticals worth $191,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ORMP. Wealth Enhancement Advisory Services LLC raised its position in shares of Oramed Pharmaceuticals by 36.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,000 shares during the last quarter. BML Capital Management LLC raised its position in shares of Oramed Pharmaceuticals by 14.3% in the 1st quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company’s stock worth $6,464,000 after purchasing an additional 376,841 shares during the last quarter. N.E.W. Advisory Services LLC raised its position in shares of Oramed Pharmaceuticals by 52.9% in the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 6,540 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 17,510 shares during the last quarter. Institutional investors own 12.73% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oramed Pharmaceuticals in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP opened at $2.39 on Friday. The firm has a market cap of $98.00 million, a price-to-earnings ratio of -6.83 and a beta of 1.62. The business has a 50-day simple moving average of $2.32 and a two-hundred day simple moving average of $2.23. Oramed Pharmaceuticals Inc. has a fifty-two week low of $1.82 and a fifty-two week high of $3.09.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, research analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current year.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.